Personalis (NASDAQ:PSNL) Earns Buy Rating from Analysts at Lake Street Capital

Lake Street Capital began coverage on shares of Personalis (NASDAQ:PSNL) in a report released on Tuesday, Benzinga reports. The brokerage issued a buy rating and a $4.00 price target on the stock.

Separately, Needham & Company LLC reissued a buy rating and issued a $3.50 price objective on shares of Personalis in a research report on Thursday, April 11th.

Personalis Price Performance

Shares of NASDAQ:PSNL traded down $0.06 during trading on Tuesday, hitting $1.54. The company had a trading volume of 355,557 shares, compared to its average volume of 364,981. The stock has a market cap of $77.77 million, a price-to-earnings ratio of -0.79 and a beta of 1.91. The company has a fifty day simple moving average of $1.46 and a two-hundred day simple moving average of $1.43. Personalis has a one year low of $0.89 and a one year high of $2.60.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.07. Personalis had a negative return on equity of 61.42% and a negative net margin of 147.38%. The company had revenue of $19.68 million during the quarter, compared to the consensus estimate of $19.56 million. On average, equities research analysts anticipate that Personalis will post -1.58 earnings per share for the current year.

Institutional Trading of Personalis

Several institutional investors and hedge funds have recently made changes to their positions in PSNL. Pathstone Family Office LLC grew its stake in Personalis by 149.3% in the 3rd quarter. Pathstone Family Office LLC now owns 37,081 shares of the company’s stock worth $45,000 after acquiring an additional 22,204 shares in the last quarter. Prime Capital Investment Advisors LLC purchased a new stake in shares of Personalis in the third quarter valued at approximately $36,000. ARK Investment Management LLC grew its stake in Personalis by 16.6% in the fourth quarter. ARK Investment Management LLC now owns 6,671,545 shares of the company’s stock worth $14,010,000 after purchasing an additional 952,118 shares in the last quarter. Bruce & Co. Inc. increased its holdings in Personalis by 100.0% during the 4th quarter. Bruce & Co. Inc. now owns 300,000 shares of the company’s stock worth $630,000 after purchasing an additional 150,000 shares during the period. Finally, Quadrature Capital Ltd bought a new position in shares of Personalis during the fourth quarter valued at approximately $152,000. 61.91% of the stock is currently owned by institutional investors.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.